These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 30550233

  • 1. Primary and Secondary Bacteremia Caused by Proteus spp.: Epidemiology, Strains Susceptibility and Biofilm Formation.
    Kwiecińska-Piróg J, Skowron K, Gospodarek-Komkowska E.
    Pol J Microbiol; 2018; 67(4):471-478. PubMed ID: 30550233
    [Abstract] [Full Text] [Related]

  • 2. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY, Chen YH, Tang HJ, Huang CC, Liao CH, Chu FY, Chuang YC, Sheng WH, Ko WC, Hsueh PR.
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Proteus mirabilis urinary tract infection and bacteremia: risk factors, clinical presentation, and outcomes.
    Chen CY, Chen YH, Lu PL, Lin WR, Chen TC, Lin CY.
    J Microbiol Immunol Infect; 2012 Jun; 45(3):228-36. PubMed ID: 22572004
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Molecular epidemiology and antimicrobial susceptibility of AmpC- and/or extended-spectrum (ESBL) ß-lactamaseproducing Proteus spp. clinical isolates in Zenica-Doboj Canton, Bosnia and Herzegovina.
    Uzunović S, Ibrahimagić A, Hodžić D, Bedenić B.
    Med Glas (Zenica); 2016 Aug 01; 13(2):103-12. PubMed ID: 27313108
    [Abstract] [Full Text] [Related]

  • 7. Bloodstream infections caused by multi-drug resistant Proteus mirabilis: Epidemiology, risk factors and impact of multi-drug resistance.
    Korytny A, Riesenberg K, Saidel-Odes L, Schlaeffer F, Borer A.
    Infect Dis (Lond); 2016 Aug 01; 48(6):428-31. PubMed ID: 26763474
    [Abstract] [Full Text] [Related]

  • 8. Catalase Activity is Critical for Proteus mirabilis Biofilm Development, Extracellular Polymeric Substance Composition, and Dissemination during Catheter-Associated Urinary Tract Infection.
    White AN, Learman BS, Brauer AL, Armbruster CE.
    Infect Immun; 2021 Sep 16; 89(10):e0017721. PubMed ID: 34280035
    [Abstract] [Full Text] [Related]

  • 9. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
    Casellas JM, Tomé G, Bantar C, Bertolini P, Blázquez N, Borda N, Couto E, Cudmani N, Guerrera J, Juárez MJ, López T, Littvik A, Méndez E, Notario R, Ponce G, Quinteros M, Salamone F, Sparo M, Sutich E, Vaylet S, Wolff L.
    Diagn Microbiol Infect Dis; 2003 Nov 16; 47(3):527-37. PubMed ID: 14596972
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial activities against biofilm formed by Proteus mirabilis isolates from wound and urinary tract infections.
    Wasfi R, Abd El-Rahman OA, Mansour LE, Hanora AS, Hashem AM, Ashour MS.
    Indian J Med Microbiol; 2012 Nov 16; 30(1):76-80. PubMed ID: 22361765
    [Abstract] [Full Text] [Related]

  • 11. Multidrug-resistant gram-negative bacterial infections in a teaching hospital in Ghana.
    Agyepong N, Govinden U, Owusu-Ofori A, Essack SY.
    Antimicrob Resist Infect Control; 2018 Nov 16; 7():37. PubMed ID: 29541448
    [Abstract] [Full Text] [Related]

  • 12. Etiologies of community-onset urinary tract infections requiring hospitalization and antimicrobial susceptibilities of causative microorganisms.
    Chiu CC, Lin TC, Wu RX, Yang YS, Hsiao PJ, Lee Y, Lin JC, Chang FY.
    J Microbiol Immunol Infect; 2017 Dec 16; 50(6):879-885. PubMed ID: 28087318
    [Abstract] [Full Text] [Related]

  • 13. Trends in antimicrobial resistance and empiric antibiotic therapy of bloodstream infections at a general hospital in Mid-Norway: a prospective observational study.
    Mehl A, Åsvold BO, Kümmel A, Lydersen S, Paulsen J, Haugan I, Solligård E, Damås JK, Harthug S, Edna TH.
    BMC Infect Dis; 2017 Feb 02; 17(1):116. PubMed ID: 28148226
    [Abstract] [Full Text] [Related]

  • 14. Urinary tract infections caused by multi-drug resistant Proteus mirabilis: Risk factors and clinical outcomes.
    Cohen-Nahum K, Saidel-Odes L, Riesenberg K, Schlaeffer F, Borer A.
    Infection; 2010 Feb 02; 38(1):41-6. PubMed ID: 19998053
    [Abstract] [Full Text] [Related]

  • 15. Microbiology and Drug Resistance of Pathogens in Patients Hospitalized at the Nephrology Department in the South of Poland.
    Michno M, Sydor A, Wałaszek M, Sułowicz W.
    Pol J Microbiol; 2018 Feb 02; 67(4):517-524. PubMed ID: 30550238
    [Abstract] [Full Text] [Related]

  • 16. Assessment of Biofilm Forming Capability and Antibiotic Resistance in Proteus mirabilis Colonizing Indwelling Catheter.
    Egbule OS, Konye OP, Iweriebor BC.
    Pak J Biol Sci; 2024 Apr 02; 27(5):268-275. PubMed ID: 38840467
    [Abstract] [Full Text] [Related]

  • 17. Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000).
    Gales AC, Sader HS, Jones RN, SENTRY Participants Group (Latin America).
    Diagn Microbiol Infect Dis; 2002 Nov 02; 44(3):289-99. PubMed ID: 12493177
    [Abstract] [Full Text] [Related]

  • 18. The incidence and beta-lactam resistance of Proteus vulgaris in hospital infections: the last decade.
    Gomez-Alferez A, Baquero F, Canton R, Loza E, Martinez-Beltran J.
    J Chemother; 1991 Oct 02; 3(5):283-8. PubMed ID: 1809807
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
    Demir T, Buyukguclu T.
    Int J Infect Dis; 2013 Nov 02; 17(11):e966-70. PubMed ID: 23742831
    [Abstract] [Full Text] [Related]

  • 20. Effects of ceftazidime and ciprofloxacin on biofilm formation in Proteus mirabilis rods.
    Kwiecińska-Piróg J, Bogiel T, Gospodarek E.
    J Antibiot (Tokyo); 2013 Oct 02; 66(10):593-7. PubMed ID: 23801185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.